Department of Cell and Chemical Biology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.
Department of Cell and Chemical Biology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.
Trends Cancer. 2021 Jun;7(6):496-510. doi: 10.1016/j.trecan.2020.11.009. Epub 2020 Dec 20.
The small ubiquitin-like modifier (SUMO) signaling cascade is critical for gene expression, genome integrity, and cell cycle progression. In this review, we discuss the important role SUMO may play in cancer and how to target SUMO signaling. Recently developed small molecule inhibitors enable therapeutic targeting of the SUMOylation pathway. Blocking SUMOylation not only leads to reduced cancer cell proliferation but also to an increased antitumor immune response by stimulating interferon (IFN) signaling, indicating that SUMOylation inhibitors have a dual mode of action that can be employed in the fight against cancer. The search for tumor types that can be treated with SUMOylation inhibitors is ongoing. Employing SUMO conjugation inhibitory drugs in the years to come has potential as a new therapeutic strategy.
小泛素样修饰物（SUMO）信号级联对于基因表达、基因组完整性和细胞周期进程至关重要。在这篇综述中，我们讨论了 SUMO 在癌症中的重要作用以及如何靶向 SUMO 信号。最近开发的小分子抑制剂使 SUMO 化途径的治疗靶向成为可能。阻断 SUMO 化不仅导致癌细胞增殖减少，而且通过刺激干扰素（IFN）信号增加抗肿瘤免疫反应，表明 SUMO 化抑制剂具有双重作用模式，可用于对抗癌症。正在寻找可以用 SUMO 化抑制剂治疗的肿瘤类型。在未来几年中使用 SUMO 连接抑制性药物具有作为新的治疗策略的潜力。
